Douglas D. Leipold

3.3k total citations
30 papers, 856 citations indexed

About

Douglas D. Leipold is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Douglas D. Leipold has authored 30 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Molecular Biology. Recurrent topics in Douglas D. Leipold's work include Monoclonal and Polyclonal Antibodies Research (20 papers), HER2/EGFR in Cancer Research (19 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Douglas D. Leipold is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (20 papers), HER2/EGFR in Cancer Research (19 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Douglas D. Leipold collaborates with scholars based in United States, France and Switzerland. Douglas D. Leipold's co-authors include Jay Tibbitts, Elaine Mai, Euan Murray, Keyang Xu, Darko Kantoci, Saileta Prabhu, Hans K. Erickson, Surinder Kaur, Gail D. Lewis Phillips and Holly A. Johnson and has published in prestigious journals such as Analytical Chemistry, Cancer Research and Analytical Biochemistry.

In The Last Decade

Douglas D. Leipold

30 papers receiving 773 citations

Peers

Countries citing papers authored by Douglas D. Leipold

Since Specialization

Citations

This map shows the geographic impact of Douglas D. Leipold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas D. Leipold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas D. Leipold more than expected).

Fields of papers citing papers by Douglas D. Leipold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas D. Leipold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas D. Leipold. The network helps show where Douglas D. Leipold may publish in the future.

Co-authorship network of co-authors of Douglas D. Leipold

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas D. Leipold. A scholar is included among the top collaborators of Douglas D. Leipold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas D. Leipold. Douglas D. Leipold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Leveraging Buprenorphine and Halofantrine as Tool Molecules to Develop a Novel Semi-Physiologically based Pharmacokinetic Model Accounting for Gastro-Intestinal Lymphatic Absorption and Enabling Cross-Species Translation 2025 ·The AAPS Journal ·Xun Tao, Shraddha Sadekar, Douglas D. Leipold, Gregory Z. Ferl, Eric Stefanich, Amrita V. Kamath	1
2	Multiplexed Quantitative Analysis of Antibody–Drug Conjugates with Labile CBI-Dimer Payloads In Vivo Using Immunoaffinity LC-MS/MS 2021 ·Analytical Chemistry ·Suk‐Joon Hyung, Douglas D. Leipold, Donna W. Lee, Surinder Kaur, Ola M. Saad	5
3	An Anti–CD22- seco -CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models 2020 ·Molecular Cancer Therapeutics ·Shang‐Fan Yu, Donna W. Lee, Bing Zheng, Geoffrey Del Rosario, Douglas D. Leipold, Helen Booler, Fiona Zhong, Montserrat Carrasco‐Triguero, Kyu Hong, Peter Yan, Rebecca K. Rowntree, Melissa M. Schutten, Thomas H. Pillow, Jack Sadowsky, Peter S. Dragovich, Andrew G. Polson	8
4	Abstract CT036: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study 2018 ·Cancer Research ·Kathleen N. Moore, (unknown), Howard A. Burris, Lisa Barroilhet, Martin Gutierrez, Judy S. Wang, Manish Patel, Michael J. Birrer, (unknown), Yulei Wang, Amit X. Garg, (unknown), Anjali Vaze, Dilip Amin, Douglas D. Leipold, S. Renee Commerford, Eric W. Humke, Joyce Liu	13
5	Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics 2017 ·Journal of Ocular Pharmacology and Therapeutics ·Vladimir Bantseev, (unknown), Douglas D. Leipold, (unknown), Paul E. Miller, Helen Booler, Evan A. Thackaberry	10
6	Attachment Site Cysteine Thiol pK_a Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody–Drug Conjugates 2017 ·Bioconjugate Chemistry ·Breanna S. Vollmar, BinQing Wei, Rachana Ohri, Jianhui Zhou, Jintang He, Shang‐Fan Yu, Douglas D. Leipold, Ely Cosino, Sharon Yee, Aimee Fourie-O’Donohue, Guangmin Li, Gail D. Lewis Phillips, Katherine R. Kozak, Amrita V. Kamath, Keyang Xu, Genee Lee, Greg A. Lazar, Hans K. Erickson	26
7	Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics 2016 ·The AAPS Journal ·Siddharth Sukumaran, Crystal Zhang, Douglas D. Leipold, Ola M. Saad, Keyang Xu, Kapil Gadkar, Divya Samineni, Bei Wang, (unknown), Montserrat Carrasco‐Triguero, Bonnee Rubinfeld, Paul J. Fielder, Kedan Lin, Saroja Ramanujan	19
8	Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates 2014 ·Cancer Chemotherapy and Pharmacology ·(unknown), Hans K. Erickson, Gail D. Lewis Phillips, (unknown), Douglas D. Leipold, Elaine Mai, Holly A. Johnson, Jay Tibbitts	22
9	A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer 2014 ·The AAPS Journal ·Brendan C. Bender, Douglas D. Leipold, Keyang Xu, Ben‐Quan Shen, Jay Tibbitts, Lena E. Friberg	64
10	American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates 2013 ·mAbs ·(unknown), Sanela Bilic, Douglas D. Leipold, William Mallet, Surinder Kaur, Bernd Meibohm, Hans K. Erickson, Jay Tibbitts, Hong Zhao, Manish Gupta	10
11	The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates 2012 ·Molecular Cancer Therapeutics ·Hans K. Erickson, Gail D. Lewis Phillips, Douglas D. Leipold, (unknown), Elaine Mai, Holly A. Johnson, Bert Gunter, Charlene A. Audette, Manish Gupta, Jan Pinkas, Jay Tibbitts	141
12	Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry 2011 ·Analytical Biochemistry ·Keyang Xu, Luna Liu, Ola M. Saad, Jakub Baudys, (unknown), Douglas D. Leipold, Ben Shen, Helga Raab, Jagath R. Junutula, Amy Kim, Surinder Kaur	122
13	Antibody Delivery of Drugs and Radionuclides: Factors Influencing Clinical Pharmacology 2011 ·Therapeutic Delivery ·Saileta Prabhu, C. Andrew Boswell, Douglas D. Leipold, Leslie A. Khawli, Dongwei Li, Dan Lü, Frank‐Peter Theil, Amita Joshi, Bert L. Lum	24
14	Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice 2010 ·Journal of Pharmacokinetics and Pharmacodynamics ·Nelson L. ‘Shasha’ Jumbe, Xin Yan, Douglas D. Leipold, Lisa Crocker, Debra L. Dugger, Elaine Mai, Mark X. Sliwkowski, Paul J. Fielder, Jay Tibbitts	90
15	Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug 2008 ·Xenobiotica ·S. Cyrus Khojasteh, Douglas D. Leipold, (unknown), (unknown), (unknown), Kelly E. Desino, (unknown), Duane C. Bloedow, Sarah Bodary, (unknown), Thomas R. Gadek, (unknown)	6
16	Development of a pharmacokinetic model examining trastuzumab-MCC-DM1, MCC-DM1 and DM1 in normal rats 2007 ·Molecular Cancer Therapeutics ·Douglas D. Leipold, (unknown), (unknown), Jakub Baudys, Ola M. Saad, Elaine Mai, Wai Lee Wong, Jay Tibbitts	1
17	Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics. 2007 ·Cancer Research ·Douglas D. Leipold, Nelson L. ‘Shasha’ Jumbe, Debra L. Dugger, Lisa Crocker, (unknown), Mark X. Sliwkowski, Damon L. Meyer, Peter D. Senter, Jay Tibbitts	3
18	Bioinversion of R‐flurbiprofen to S‐flurbiprofen at various dose levels in rat, mouse, and monkey 2004 ·Chirality ·Douglas D. Leipold, Darko Kantoci, Euan Murray, (unknown), William J. Wechter	22
19	Treatment and survival study in the C57BL/6J-APCMin/+ (Min) mouse with R-flurbiprofen 2000 ·Life Sciences ·William J. Wechter, Euan Murray, Darko Kantoci, (unknown), Douglas D. Leipold, (unknown), (unknown)	55
20	Mechanism of Enhancement of Intestinal Ulcerogenicity of S-Aryl Propionic Acids by Their R-Enantiomers in the Rat 1998 ·Digestive Diseases and Sciences ·William J. Wechter, (unknown), Darko Kantoci, Euan Murray, (unknown), Douglas D. Leipold, (unknown), (unknown), (unknown)	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact